CL-82198-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemECL-82198Cat.No.:HY-100359CASNo.:307002-71-7分⼦式:C₁₇H₂₂N₂O₃分⼦量:302.37作⽤靶点:MMP作⽤通路:MetabolicEnzyme/Protease储存⽅式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性数据体外实验DMSO:100mg/mL(330.72mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制备储备液1mM3.3072mL16.5360mL33.0721mL5mM0.6614mL3.3072mL6.6144mL10mM0.3307mL1.6536mL3.3072mL请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。储备液的保存⽅式和期限：-80°C,6months;-20°C,1month。-80°C储存时，请在6个⽉内使⽤，-20°C储存时，请在1个⽉内使⽤。体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(8.27mM);Clearsolution1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(8.27mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(8.27mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性CL-82198⼀个选择性的MMP-13抑制剂。CL-82198与MMP-13的整个S1'⼝袋结合，这其对MMP-13选择性和对其他MMP缺乏抑制活性的础。CL-82198可⽤于⾻关节炎(OA)的研究。体外研究CL-82198(10μM;24hours)significantlyreducesLS174cellmigration[1].CL-82198decreasesCTGFandTGF-β1proteinlevelsinhepaticstellatecells[3].体内研究CL82198(1-10mg/kg;i.p.;everyotherdayfor12weeks)preventsanddeceleratesMLI-inducedosteoarthritisprogression[4].AnimalModel:10-week-oldC57BL/6Jmice(performedMLIsurgery)[4]Dosage:1,5,10mg/kgbodyweightAdministration:Intraperitonealinjection;everyotherdayfor12weeksResult:PreventedanddeceleratedMLI-inducedosteoarthritisprogression.户使⽤本产品发表的科研⽂献•NatCommun.2022Jul11;13(1):4007.•JCellPhysiol.2019Sep;234(9):15395-15406.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].RathTetal.Matrixmetalloproteinase-13isregulatedbytoll-likereceptor-9incolorectalcancercellsandmediatescellularmigration.OncolLett.2011May;2(3):483-488.[2].WohlauerMetal.Nebulizedhypertonicsalineattenuatesacutelunginjuryfollowingtraumaandhemorrhagicshockviainhibitionofmatrixmetalloproteinase-13.CritCareMed.2012Sep;40(9):2647-53.[3].GeorgeJ,etal.MMP-13deletiondecreasesprofibrogenicmoleculesandattenuatesN-nitrosodimethylamine-inducedliverinjuryandfibrosisinmice.JCellMolMed.2017Dec;21(12):3821-3835.[4].WangM,etal.MMP13isacriticaltargetgeneduringtheprogressionofosteoarthritis.ArthritisResTher.2013Jan8;15(1):R5.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalappli